Recently the Food and Drug Administration (FDA) submitted draft guidance on marijuana and CBD research to the White House Office of Management and Budget (OMB).
The document is entitled “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.” An FDA spokesperson indicated to Marijuana Moment that the document is in regards to the agency’s ongoing work to develop broader CBD regulations that could eventually allow for the marketing of cannabis products as dietary supplements or food items.
“We recognize that there is substantial public interest in marketing and accessing CBD for a variety of products. We are working toward a goal of providing additional guidance, and have made substantial progress,” the FDA said. “There are many questions to explore regarding the science, safety, effectiveness and quality of products containing CBD, and we need to do our due diligence.”
“As part of our work, the FDA continues to explore potential pathways for various types of CBD products to be lawfully marketed,” the FDA added. “An important component of this work is obtaining and evaluating information to address outstanding questions related to the safety of CBD products that will inform our consideration of potential regulatory frameworks for CBD while maintaining the FDA’s rigorous public health standards.”
“We will continue to update the public about our path forward as our work progresses, and provide information that is based on sound science and data,” the FDA said.